Skip to main content
Quest Diagnostics

Consequences of the COVID-19 Pandemic: Reduced Hemoglobin A1c Diabetes Monitoring

Consequences of the COVID-19 Pandemic: Reduced Hemoglobin A1c Diabetes Monitoring

Authors: Fragala MS, Kaufman HW, Meigs JB, Niles JK, McPhaul MJ

Citation: Popul Health Manag. 2020 Jun 30; doi: 10.1089/pop.2020.0134 [Online ahead of print.]

Specialties: COVID-19, Infectious Disease, Endocrinoogy

Download key summary

Related content

Publication
Rise in Blood Pressure Observed Among US Adults During the COVID-19 Pandemic
Publication
Large-scale retrospective analyses of the effect of iron deficiency anemia on hemoglobin A1c concentrations
Publication
Changes in the Number of US Patients With Newly Identified Cancer Before and During the Coronavirus Disease 2019 COVID 19 Pandemic
Publication
The Long-term Health Consequences of COVID-19

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.